Orallyactive,potentinhibitorofphosphodiesterase5(PDE5)(IC50=4nM).Enhancesnitricoxide-dependentrelaxationofhumancorpuscavernosuminvitro.
SoldforresearchpurposesunderagreementfromPfizerInc.
SildenafilcitrateisalsoofferedaspartoftheTocriscreenPlusandTocriscreenLibraryofFDA-ApprovedCompounds.FindoutmoreaboutcompoundlibrariesavailablefromTocris.
M.Wt | 666.7 |
Formula | C22H30N6O4S.C6H8O7 |
Storage | DesiccateatRT |
Purity | ≥99%(HPLC) |
CASNumber | 171599-83-0 |
PubChemID | 62853 |
InChIKey | DEIYFTQMQPDXOT-UHFFFAOYSA-N |
Smiles | O=C(O)C(O)(CC(O)=O)CC(O)=O.CN1CCN(S(C2=CC=C(OCC)C(C(NC4=C3N(C)N=C4CCC)=NC3=O)=C2)(=O)=O)CC1 |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Solvent | MaxConc.mg/mL | MaxConc.mM | |
---|---|---|---|
Solubility | |||
DMSO | 66.67 | 100 |
Thefollowingdataisbasedontheproductmolecularweight666.7.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
---|---|---|---|
1mM | 1.5mL | 7.5mL | 15mL |
5mM | 0.3mL | 1.5mL | 3mL |
10mM | 0.15mL | 0.75mL | 1.5mL |
50mM | 0.03mL | 0.15mL | 0.3mL |